Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

Investors may be wary of AJANTPHARM as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.042715
debtToEquity 1.343000
earningsGrowth 0.046000
revenueGrowth 0.138000
grossMargins 0.760520
operatingMargins 0.257330
trailingEps 74.330000
forwardEps 99.280000

Ajanta Pharma Limited's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
With positive gross and operating margins, Ajanta Pharma Limited's profitability is evident. These metrics suggest the company is efficiently managing its expenses while maintaining strong revenue, highlighting a solid financial foundation.
AJANTPHARM's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that AJANTPHARM is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

Over time, analysts have gradually revised AJANTPHARM's price projections downward. This suggests growing concerns about the company's ability to meet previous expectations, pointing to a more conservative outlook.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


14 separate sales of AJANTPHARM shares were executed, with the market price hovering at 2891.067853655134.During the period under consideration, no sell transactions took place.The recent buying activity at current Ajanta Pharma Limited price levels exceeds selling, suggesting a potential positive outlook. Investors may see this trend as an indicator that the stock is likely to perform well, reflecting growing confidence.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Analysts have maintained a buy bias for AJANTPHARM, which could prompt investors to consider the stock as a viable investment. With this positive outlook, AJANTPHARM is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.